Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Toshihide Okadome"'
Autor:
Fernando López-Casillas, Toshihide Okadome, M. Magdalena Vilchis-Landeros, Kohei Miyazono, José Luis Montiel, José Esparza-López
Publikováno v:
Journal of Biological Chemistry. 276:14588-14596
Betaglycan, also known as the transforming growth factor-β (TGF-β) type III receptor, is a membrane-anchored proteoglycan that binds TGF-β via its core protein. Deletion mutagenesis analysis has revealed two regions of betaglycan ectodomain capabl
Autor:
Peter ten Dijke, Isabelle Neveu, Toshihide Okadome, Natale Belluardo, Mikael Rydén, Miles Trupp, Henrik Jörnvall, Carlos F. Ibáñez, Takeshi Imamura
Publikováno v:
Journal of Biological Chemistry. 271:30603-30609
Receptor serine-threonine kinases (RSTK) mediate inhibitory as well as stimulatory signals for growth and differentiation by binding to members of the transforming growth factor-beta (TGF-beta) superfamily. Over 12 different RSTKs have been isolated
Autor:
Takeshi Imamura, Hideomi Yamashita, G N Cox, Bradley Rosenzweig, C H Heldin, P. ten Dijke, Kohei Miyazono, Toshihide Okadome
Publikováno v:
Proceedings of the National Academy of Sciences. 92:7632-7636
Bone morphogenetic proteins (BMPs) are members of the transforming growth factor beta superfamily. Several members of this family have been shown to transduce their signals through binding to type I and type II serine-(threonine) kinase receptors. He
Autor:
Toshihide Okadome, Carl-Henrik Heldin, Hidetoshi Yamashita, Peter ten Dijke, Kohei Miyazono, Petra Franzen
Publikováno v:
Journal of Biological Chemistry. 270:770-774
A rat pituitary tumor cell line (GH3) has been reported to express transforming growth factor-beta (TGF-beta) binding components of 70-74 kDa (ligand included), denoted TGF-beta type IV receptor. We investigated whether the type IV receptor correspon
Autor:
Petra Franzen, Anita Morén, C H Heldin, Kohei Miyazono, Toshihide Okadome, Hidetoshi Yamashita
Publikováno v:
Journal of Biological Chemistry. 269:30753-30756
Transforming growth factor-beta (TGF-beta) transduces signals through binding to type I (T beta R-I) and type II (T beta R-II) serine/threonine kinase receptors. T beta R-I requires T beta R-II for ligand binding, whereas T beta R-II requires T beta
Publikováno v:
Japanese Journal of Thrombosis and Hemostasis. 2:207-211
In order to elucidate the relationship between antiphospholipid antibody (APLA) and thrombotic tendency, we studied the changes in the blood coagulation system in 31 positive APLA patients using thrombin-antithrombin III complex (TAT) and β-thrombog
Publikováno v:
Japanese Journal of Thrombosis and Hemostasis. 2:48-56
In 12 patients with nephrotic syndrome, the moleclar markers for hypercoagulability including thrombin-antithrombin III complex (TAT), plasmin-α2-plasmin inhibitor complex (PIC) and β-thromboglobulin (β-TG), and the coagulation regulatory factors
Autor:
Toshihide Okadome, Harold L. Moses, Hidenori Ichijo, Eiichi Oeda, Masao Saitoh, Masahiro Kawabata, Kohei Miyazono
Publikováno v:
The Journal of biological chemistry. 271(36)
The type I transforming growth factor-beta receptor (TbetaR-I) is the efferent component of the receptor complex, which presumably phosphorylates intracellular targets. FKBP12, a binding protein for FK506 and rapamycin, is shown to associate with the
Autor:
Shuji Izumo, Mitsutoshi Tara, Yoshitaka Furukawa, Kiyoshige Niina, Toshihide Okadome, Mitsuhiro Osame
Publikováno v:
Internal medicine (Tokyo, Japan). 34(11)
We report a 47-year-old Japanese woman with HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) combined with acute type adult T-cell leukemia (ATL). The susceptibility for HAM/TSP and acute type of ATL is hitherto explained by human
Autor:
Kanji Sato, Yoshifusa Koreeda, Hidehito Imamura, Kiyoshige Niina, Kazuoki Ohsumi, Kazuo Shizume, Toshihide Okadome, Mitutoshi Tara
Publikováno v:
Japanese journal of clinical oncology. 22(5)
Hypercalcemia with adult T-cell leukemia (ATL) is chiefly caused by an excessive production by tumor cells of parathyroid hormone-related protein (PTHrP). We have previously reported hypercalcemic patients with solid tumors to excrete a large amount